Skip to main content

Table 1 Baseline characteristics, EORTC QLQ-C30 scores and EQ-5D-5L scores (ITT population)

From: Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Characteristic

D-VMP (n = 350)

VMP (n = 356)

Age, years

 Mean (SD)

71.3 (6.66)

71.5 (5.82)

  < 65, n (%)

36 (10.3)

24 (6.7)

 65 to < 75, n (%)

210 (60.0)

225 (63.2)

  ≥ 75, n (%)

104 (29.7)

107 (30.1)

Male, n (%)

160 (45.7)

167 (46.9)

Race, n (%)

 White

297 (84.9)

304 (85.4)

 Black or African American

3 (0.9)

3 (0.8)

 Asian

47 (13.4)

45 (12.6)

 Other, Unknown or Not reported

3 (0.9)

4 (1.1)

ECOG performance status, n (%)

 0

78 (22.3)

99 (27.8)

 1

182 (52.0)

173 (48.6)

 2

90 (25.7)

84 (23.6)

EORTC QLQ-C30 GHS score, mean (SD)

 GHS

50.74 (20.996)

52.40 (22.691)

EORTC QLQ-C30 functional scores, mean (SD)

 Physical functioning

59.96 (26.756)

63.65 (25.701)

 Role functioning

57.54 (34.250)

61.06 (33.192)

 Emotional functioning

69.70 (24.735)

71.10 (22.304)

 Cognitive functioning

80.49 (21.998)

83.38 (19.948)

 Social functioning

70.41 (28.468)

70.64 (28.651)

EORTC QLQ-C30 symptom scores, mean (SD)

 Pain

46.10 (33.130)

43.12 (31.429)

 Fatigue

42.48 (25.661)

41.05 (25.798)

 Nausea/vomiting

5.38 (12.425)

5.45 (13.566)

 Dyspnea

18.35 (24.930)

19.37 (24.742)

 Insomnia

29.54 (30.044)

27.93 (31.135)

 Appetite loss

22.26 (28.116)

21.81 (26.623)

 Constipation

23.00 (31.517)

18.86 (27.404)

 Diarrhea

5.91 (17.015)

5.40 (15.270)

 Financial difficulties

18.88 (26.534)

17.33 (24.743)

EQ-5D-5L scores, mean (SD)

(n = 316)

(n = 325)

 VAS

57.72 (20.254)

60.32 (20.556)

  1. SD standard deviation
  2. Higher EORTC QLQ-C30 scores represent greater GHS, better functioning and worse symptoms. Higher EQ-5D-5L VAS score represents better health